to License Agreement between Argos Therapeutics, Inc. (hereinafter “Argos”) - and - Lummy (Hong Kong) Co., Ltd. (hereinafter “China Company”) This Amendment is made as of and effective March 23th, 2018 (“Effective Date”), contingent on the full...License Agreement • April 2nd, 2018 • Argos Therapeutics Inc • Pharmaceutical preparations
WHEREAS, Argos and China Company entered into a license agreement dated April 7, 2015 (the “License Agreement”), as first amended on December 5, 2016, and amended a second time on October 19, 2017;
Evaluation and Option Agreement for a Patent LicenseEvaluation and Option Agreement • April 2nd, 2018 • Argos Therapeutics Inc • Pharmaceutical preparations • England and Wales
This Evaluation and Option Agreement for a Patent License ("Agreement"), dated as of February 1, 2018 ("Effective Date"), is by and between Actigen Limited (“Patent Holder”) Pharmstandard International, S.A. ("Prospective Licensor") and Argos Therapeutics, Inc. ("Prospective Sublicensee").
to License Agreement between Argos Therapeutics, Inc. (hereinafter “Argos”) - and - Lummy (Hong Kong) Co., Ltd. (hereinafter “China Company”) This Amendment is made as of and effective _2017-10-18__________ (“Effective Date”), contingent on the full...License Agreement • April 2nd, 2018 • Argos Therapeutics Inc • Pharmaceutical preparations
WHEREAS, Argos and China Company entered into a license agreement dated April 7, 2015 (the “License Agreement”), as first amended on December 5, 2016;
